Secondary Progressive Multiple Sclerosis

Transcription

1 Secondary Progressive Multiple Sclerosis A Detailed Overview Pharmascroll A Pharmascroll Publication This publication is meant to be used only for Pharmascroll clients post subscription.

2 Table of Contents 1. Multiple Sclerosis Definition Types of Multiple Sclerosis...10 a. Relapsing Remitting MS.10 b. Secondary Progressive MS...10 c. Primary Progressive MS.11 d. Progressive Relapsing MS Secondary Progressive Relapsing MS Defined Causes of SPMS Profile of SPMS Patient Symptoms of SPMS Disease progression and impact on QoL Disease Diagnosis...20 a. Disease diagnosis through symptoms..20 b. Disease diagnosis through medical tests Disease Epidemiology 23 a. US Epidemiology.23 b. UK Epidemiology.24 c. Germany Epidemiology.25 d. Italy Epidemiology..26 e. France Epidemiology.27 f. Spain Epidemiology...28 Secondary Progressive Multiple Sclerosis- A Detailed Overview 1

3 g. Japan Epidemiology Factors impacting a physician s prescription decision.30 a. Efficacy 31 b. Tolerability and Safety.33 c. Monitoring Requirements...36 d. Pricing and Reimbursement Disease Modifying Therapies for SPMS.39 a. Laquinimod 39 i. About the Product 39 ii. Patent and Trial Details...40 iii. Impact of Laquinimod..42 b. Lemtrada..43 i. About the Product.43 ii. Patent and Trial Details 44 iii. Impact of Lemtrada...45 c. Masitinib...46 i. About the Product..46 ii. Patent and Trial Details.47 iii. Impact of Masitinib. 48 d. Ocrelizumab i. About the Product..49 ii. Patent and Trial Details.50 iii. Impact of Ocrelizumab.. 52 Secondary Progressive Multiple Sclerosis- A Detailed Overview 2

4 e. Tysabri...53 i. About the Product..53 ii. Patent and Trial Details.54 iii. Impact of Tysabri 55 f. Siponimod i. About the Product..56 ii. Patent and Trial Details.57 iii. Impact of Siponimod.. 58 g. Zinbryta..59 i. About the Product...59 ii. Patent and Trial Details..60 iii. Impact of Zinbryta...61 h. Mitoxantrone i. About the Product...62 ii. Patent and Trial Details..63 iii. Impact of Mitoxantrone..64 i. Ponesimod i. About the Product...65 ii. Patent and Trial Details..66 iii. Impact of Ponesimod Drug Attribute Analysis.68 a. Laquinimod 68 b. Lemtrada 69 Secondary Progressive Multiple Sclerosis- A Detailed Overview 3

5 c. Masitinib 71 d. Ocrelizumab.72 e. Ponesimod...74 f. Siponimod 75 g. Tysabri..77 h. Zinbryta 79 i. Mitoxantrone Other Pipeline Products...81 a. Number of Pipeline Products phase wise...82 b. Number of Companies having other pipeline products phase wise SPMS Market Sizing..84 a. Laquinimod.84 i. Value sales in SPMS indication..84 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.85 iv. Patient numbers by key geographies/countries...85 b. Lemtrada..86 i. Value sales in SPMS indication..86 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.87 iv. Patient numbers by key geographies/countries...87 c. Masitinib...88 i. Value sales in SPMS indication..88 Secondary Progressive Multiple Sclerosis- A Detailed Overview 4

6 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.89 iv. Patient numbers by key geographies/countries...89 d. Ocrelizumab.90 i. Value sales in SPMS indication..90 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.91 iv. Patient numbers by key geographies/countries...91 e. Ponesimod...92 i. Value sales in SPMS indication..92 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.93 iv. Patient numbers by key geographies/countries...93 f. Siponimod...94 i. Value sales in SPMS indication..94 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.95 iv. Patient numbers by key geographies/countries...95 g. Tysabri..96 i. Value sales in SPMS indication..96 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.97 iv. Patient numbers by key geographies/countries...97 Secondary Progressive Multiple Sclerosis- A Detailed Overview 5

7 h. Zinbryta i. Value sales in SPMS indication..98 ii. Patient numbers in SPMS indication iii. Value sales by key geographies/countries.99 iv. Patient numbers by key geographies/countries Market Sizing Country Wise 100 a. Global 100 i. Value sales by Brand 100 ii. Patient numbers by Brand..100 b. US i. Value sales by Brand 101 ii. Patient numbers by Brand..101 c. Germany i. Value sales by Brand 102 ii. Patient numbers by Brand..102 d. France i. Value sales by Brand 103 ii. Patient numbers by Brand..103 e. Italy 104 i. Value sales by Brand 104 ii. Patient numbers by Brand..104 f. Spain. 105 i. Value sales by Brand 105 Secondary Progressive Multiple Sclerosis- A Detailed Overview 6

8 ii. Patient numbers by Brand..105 g. UK i. Value sales by Brand 106 ii. Patient numbers by Brand..106 h. Canada i. Value sales by Brand 107 ii. Patient numbers by Brand..107 i. Australia i. Value sales by Brand 108 ii. Patient numbers by Brand..108 Secondary Progressive Multiple Sclerosis- A Detailed Overview 7